![](https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1-260x180.png)
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1-260x180.png)
![](https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos-260x180.png)
Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia
Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper”…
![](https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1-260x185.png)
Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”),…
![](https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1-260x180.jpg)
Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024
- Late-breaking abstract on extended follow-up data from…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1-260x180.png)
Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
Raises additional 16M EUR led by Dawn Biopharma, a platform…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics
Under the agreement terms, J&J will pay $1.25 billion…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1-260x180.png)
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
The Board of Directors of Calliditas Therapeutics AB (publ) unanimously…
![](https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1-260x180.jpg)
Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference
Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1-260x180.png)
STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
STC-15 is the first METTL3 inhibitor to enter clinical development
Clinical…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings Boston office named a 2024 Best Place to Work by the Boston Business Journal
Investment firm’s connection to the Novo Nordisk Foundation…
![](https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1-260x180.png)
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE:…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/DelSiTech_Logo_300px-1-260x180.png)
Delsitech announces a major licensing agreement on drug delivery
Turku, Finland – 23rd May, 2024. Clinical-stage drug delivery…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1-260x180.png)
Bacteria in our gut could play a role in cardiometabolic disease: A new initiative aims to find out
A new Denmark-based research initiative aims to establish a potential…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/Neophare_Logo_300px-1-260x180.png)
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Additional funding will be used to explore novel biology around…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/Baselaunch_Logo_300px-2-260x180.png)
BaseLaunch announces a new partnership with AbbVie
Media release
Basel, Switzerland, 22.05.2024
BaseLaunch announces…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1-260x180.png)
Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
Financing led by TCGX, including new investment from BVF…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings and A.P. Moller Holding back CIRCTEC, a leader in pyrolysis for sustainable end-of-life tyre recycling, in a €150 million financing round
Novo Holdings and A.P. Moller Holding have enabled a €150…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1-260x180.png)
One in three people die due to atherosclerosis: A new initiative aims to find new ways to prevent it
Globally, cardiovascular diseases due to atherosclerosis –…
![](https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4-260x180.png)
Novo Holdings to acquire majority stake in Single Use Support
Novo Holdings A/S (“Novo Holdings”) today announced…
![](https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2-260x180.png)
Publication in Nature Immunology outlining the contribution of B cells to anticancer immunosurveillance highlights Alchemab’s capabilities and potential to develop new cancer therapies
Cambridge, UK, 14 May 2024 – Alchemab Therapeutics (Alchemab),…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York